scholarly journals Patient’s satisfaction beyond hand function in Dupuytren’s disease: analysis of 1106 patients

2019 ◽  
Vol 45 (3) ◽  
pp. 280-285 ◽  
Author(s):  
Ralph Poelstra ◽  
Yara E. van Kooij ◽  
Mark J. W. van der Oest ◽  
Harm P. Slijper ◽  
Steven E. R. Hovius ◽  
...  
Keyword(s):  
Patient Satisfaction ◽  
Hand Function ◽  
Dupuytren’S Disease ◽  
Extension Deficit ◽  
Level Of Evidence ◽  
Dupuytren's Disease ◽  
Patient’S Satisfaction ◽  
Patient Reported ◽  
Limited Fasciectomy ◽  
Disease Analysis

This study investigates the outcomes of 1106 patients with Dupuytren’s disease treated with limited fasciectomy or percutaneous needle fasciotomy over 16 years according to the different domains of patient-reported hand function. These patients completed the Michigan Hand Outcomes Questionnaire before and 3 months after surgery. Scores for the various outcome parameters were calculated and linear regression analyses were used to examine associations between the changes in digital extension deficit and change in Michigan Hand Outcomes Questionnaire (sub)scores. We found the largest effects of surgical treatment in the decreases in extension deficit, the appearance of the hand, and the satisfaction with the hand function. However, associations between different domains of evaluation were weak. We conclude that improvement of digital extension deficits is not parallel to varying aspects of patient satisfaction. The findings underline the importance of assessing domains relating to patient satisfaction other than objective hand function measures in Dupuytren’s disease. Level of evidence: IV

scholarly journals Better patients’ treatment experiences are associated with better postoperative results in Dupuytren’s disease

2018 ◽  
Vol 43 (8) ◽  
pp. 848-854 ◽  
Author(s):  
Ralph Poelstra ◽  
Ruud W. Selles ◽  
Harm P. Slijper ◽  
Mark J.W. van der Oest ◽  
Reinier Feitz ◽  
...  
Keyword(s):  
Treatment Outcomes ◽  
Healthcare Delivery ◽  
Dupuytren’S Disease ◽  
Postoperative Treatment ◽  
Extension Deficit ◽  
Level Of Evidence ◽  
Dupuytren's Disease ◽  
Patient Reported ◽  
Treatment Context ◽  
Limited Fasciectomy

This prospective study investigates the extent to which a better experience with healthcare delivery is associated with better postoperative treatment outcomes after surgery for Dupuytren’s contracture. Patients undergoing limited fasciectomy or percutaneous needle fasciotomy for Dupuytren’s contractures completed the Michigan Hand Outcomes Questionnaire before and 3 months after surgery, together with a patient reported experience measure, while hand therapists assessed the straightness of the finger with a goniometer. Regression analyses were used to examine associations. We found that a better experience with healthcare delivery was associated with better patient-reported outcomes, while association with residual extension deficit was minimal. Strongest associations were seen with communication of the physician, postoperative care and information about the treatment. Experience with the treatment explained up to 12% of the variance in treatment outcome. These findings suggest that patient reported treatment outcomes in Dupuytren’s disease can be improved by improving the treatment context. Level of evidence: II

The influence of skin tears following collagenase treatment of Dupuytren’s disease on treatment outcomes

2020 ◽  
pp. 175319342094132
Author(s):  
Robert Phan ◽  
Warren M. Rozen ◽  
Giselle Dela Cruz ◽  
Vicky Tobin ◽  
David J. Hunter-Smith
Keyword(s):  
Patient Reported Outcomes ◽  
Dupuytren’S Disease ◽  
Extension Deficit ◽  
Level Of Evidence ◽  
Dupuytren's Disease ◽  
Finger Extension ◽  
Patient Reported ◽  
Collagenase Injection ◽  
Skin Tears ◽  
Pre Treatment

This study investigated influence of skin tears on patient-reported outcomes of injection of collagenase clostridium histolyticum for Dupuytren’s disease and association between extension deficit of digits before injection and skin tear after the injection. From 2016 to 2018, 391 Dupuytren’s cords were treated in 184 patients in a prospective cohort study and the patients were evaluated before injection and six months after injection. Skin tears occurred in 50% of these patients. We found no significant differences in the patient-reported outcomes between patients with or without skin tears. A higher extension deficit before treatment was associated with significantly increased frequency of skin tears. We conclude that the incidence of skin tears after injection does not affect patient reported outcomes six months after collagenase injection, but the incidence of skin tears is significantly associated with the severity of pre-treatment finger extension deficits. Level of evidence: II

Dupuytren's Contracture. The Safety and Efficacy of Collagenase Treatment

2016 ◽  
Vol 21 (02) ◽  
pp. 187-192 ◽  
Author(s):  
Adalsteinn Odinsson ◽  
Lars Erik Brenne ◽  
Tone Bøyesen Lurie ◽  
Vilhjalmur Finsen
Keyword(s):  
Patient Satisfaction ◽  
Hand Function ◽  
Primary Treatment ◽  
Dupuytren’S Disease ◽  
Successful Outcome ◽  
Extension Deficit ◽  
Serious Adverse Events ◽  
Dupuytren's Disease ◽  
Collagenase Injection ◽  
New Treatment

Background: Our main goal was to see if treatment with collagenase injection is safe and effective and to assess patient satisfaction with this new treatment. Methods: We prospectively followed 77 consecutive patients, treated for contracture in 91 fingers and 142 joints that received total of 109 collagenase injections. The patients were reviewed on the first and second day and at 4 and 12 months. A contracture reduced to five degrees or less at 12 months after the last injection, was considered to be a successful outcome. Results: A mean of 1.2 injections were used per patient and 0.8 injections per joint. There was a significant improvement in mean passive extension deficit. Out of the 142 joints treated, 84 (59%) met our criterion for a successful outcome; 56 (80%) out of 70 MCP joints and 28 (39%) out of 72 PIP joints. There were also significant improvements in both hand function and pain. No serious adverse events were observed. The mean patient satisfaction with the treatment at the 12-month follow up was a VAS score of 78 (0 = none; 100 = complete) and only 11% stated that they would not have consented to the treatment if they had known the outcome in advance. Conclusions: Treatment of Dupuytren's disease with collagenase injection is both safe and effective. It is now our primary treatment for Dupuytren's disease.

scholarly journals Hand function 5 years after treatment with collagenase Clostridium histolyticum injection for Dupuytren’s disease

2021 ◽  
pp. 175319342110023
Author(s):  
Ingrid Göransson ◽  
Lars Brudin ◽  
Andra Irbe ◽  
Christina Turesson
Keyword(s):  
Range Of Motion ◽  
Hand Function ◽  
Treatment Method ◽  
Dupuytren’S Disease ◽  
Collagenase Clostridium Histolyticum ◽  
Extension Deficit ◽  
Level Of Evidence ◽  
Dupuytren's Disease ◽  
Clostridium Histolyticum ◽  
New Treatment

The aim of this study was to report hand function, disability and satisfaction and patients’ perception of functionally troublesome contractures 5 years after injection with collagenase Clostridium histolyticum and hand therapy for Dupuytren's disease. Data from 79 patients were collected before and at 3, 12 and 60 months after treatment. Hand function was significantly improved, and 70% achieved a functional range of motion in the treated hand. QuickDASH scores and range of motion were best at 3 months follow-up. At 60 months, mean total extension deficit was 48°, which was 57% of the deficit before treatment. Thirty-seven patients (47%) had developed recurrent contractures in treated finger(s) meeting the criteria for new treatment. The threshold for functionally troublesome contractures was found to be 30°–60° in the finger joints. Treatment was experienced as painful, but few hand function problems occurred. Most patients would choose this treatment method again. Level of evidence: IV

scholarly journals Measurement properties of the Dutch Unité Rhumatologique des Affections de la Main and its ability to measure change due to Dupuytren’s disease progression compared with the Michigan Hand outcomes Questionnaire

2018 ◽  
Vol 43 (8) ◽  
pp. 855-863 ◽  
Author(s):  
Dieuwke C. Broekstra ◽  
Edwin R. van den Heuvel ◽  
Rosanne Lanting ◽  
Paul M. N. Werker
Keyword(s):  
Disease Progression ◽  
Hand Function ◽  
Dupuytren’S Disease ◽  
Receiver Operating Curve ◽  
Measurement Properties ◽  
Minimal Important Change ◽  
Level Of Evidence ◽  
Dupuytren's Disease ◽  
Smallest Detectable Change ◽  
Prospective Longitudinal

Data of a prospective longitudinal cohort study including 233 Dupuytren’s patients was used to determine: (1) whether the Unité Rhumatologique des Affections de la Main scale and Michigan Hand outcomes Questionnaire can detect change in hand function due to Dupuytren’s disease progression and to compare their abilities; (2) the concurrent validity, reliability, responsiveness and interpretability of the Dutch Unité Rhumatologique des Affections de la Main. The Unité Rhumatologique des Affections de la Main and Michigan Hand outcomes Questionnaire had comparable measurement properties, and were both able to distinguish participants with disease progression from those without progression (resp. U = 1252.5, p = 0.008, and U = 1086.0, p < 0.001), but only at a group level. Individual cases of progression could not be detected using these outcome measures, as indicated by the fact that the smallest detectable change was larger than the minimal important change, and area under the receiver operating curve (AUC) values of 0.75 for Michigan Hand outcomes Questionnaire and 0.67 for Unité Rhumatologique des Affections de la Main. Level of evidence: II

Validity of the Disabilities of the Arm, Shoulder and Hand patient-reported outcome measure (DASH) and the Quickdash when used in Dupuytren’s disease

2015 ◽  
Vol 41 (6) ◽  
pp. 589-599 ◽  
Author(s):  
J. Rodrigues ◽  
W. Zhang ◽  
B. Scammell ◽  
P. Russell ◽  
I. Chakrabarti ◽  
...  
Keyword(s):  
Outcome Measure ◽  
Patient Reported Outcome ◽  
Postoperative Recovery ◽  
Summary Score ◽  
Dupuytren’S Disease ◽  
Validity And Reliability ◽  
Level Of Evidence ◽  
Dupuytren's Disease ◽  
Patient Reported Outcome Measure ◽  
Patient Reported

This study investigated aspects of the validity and reliability of the 30-item Disabilities of the Arm, Shoulder and Hand patient-reported outcome measure (DASH) and its relationship with the shorter 11-item QuickDASH in patients with Dupuytren’s disease. Seven hundred and fifty-nine DASH questionnaires were studied, covering pre- and postoperative patients undergoing different treatments for Dupuytren’s disease. Items related to pain rose early after treatment before returning to baseline, suggesting that studying pain is relevant during postoperative recovery. Across all 759 sets of responses, the QuickDASH agreed closely with the DASH. In exploratory factor analysis, the DASH was not unidimensional, questioning the validity of the DASH summary score in Dupuytren’s disease. Further validation of existing PROMs for use in Dupuytren’s disease is needed. These data suggest that pain is a relevant symptom to study during postoperative recovery following treatment for Dupuytren’s disease. Level of evidence: III.

scholarly journals Different collagenase delivery for Dupuytren disease in public hospitals

2020 ◽  
Vol 3 (2) ◽  
pp. 22-31
Author(s):  
Jessca A Paynter ◽  
Vicky Tobin ◽  
James CS Leong ◽  
Warren Matthew Rozen ◽  
David J Hunter-Smith
Keyword(s):  
Clinical Success ◽  
Patient Reported Outcome Measures ◽  
Patient Reported Outcome ◽  
Public Hospitals ◽  
Dupuytren’S Disease ◽  
Patient Specific ◽  
Extension Deficit ◽  
Dupuytren's Disease ◽  
Number Of Patients ◽  
Patient Reported

Background: The delivery protocol of collagenase Clostridium histolyticum (collagenase) injection for Dupuytren’s disease is variable, due to limited evidence for any one approach and widespread ‘off-label’ delivery occurring in Australia. As such, this preliminary study aimed to assess whether different collagenase delivery protocols for treating Dupuytren’s disease have an impact on effectiveness and safety. It was hypothesised that different collagenase delivery would affect outcomes. Methods: This preliminary, prospective study included a consecutive cohort of adult patients with Dupuytren’s disease being treated with collagenase within two Australian public hospitals to determine whether different collagenase delivery protocols impact on effectiveness and safety. The therapeutic effect was measured objectively using the total passive extension deficit (TPED), clinical success and clinical improvement. Three patient-reported outcome measures (PROMs) were used: Unité Rhumatologique des Affections de la Main (URAM), the Southampton Dupuytren’s Scoring Scheme and the Canadian Occupational Patient-Specific Functional Scale (PSFS). Results: The delivery of collagenase was variable at both clinics. The number of patients treated with collagenase at Institute I and Institute II was 49 and 18, respectively. Clinical success was achieved in 42 per cent of the Institute I and 35 per cent of the Institute II cohort. A statistically significant reduction in all three PROMs was observed for both cohorts. No significant differences between effectiveness or safety was found when comparing the two cohorts. Conclusion: The delivery of collagenase was variable at Institutes I and II, but these differences did not appear to impact the effectiveness or safety of collagenase delivery.

Prevalence and incidence of doctor-diagnosed Dupuytren’s disease: a population-based study

2017 ◽  
Vol 42 (7) ◽  
pp. 673-677 ◽  
Author(s):  
J. Nordenskjöld ◽  
M. Englund ◽  
C. Zhou ◽  
I. Atroshi
Keyword(s):  
General Population ◽  
International Classification Of Diseases ◽  
Population Based ◽  
Dupuytren’S Disease ◽  
Level Of Evidence ◽  
Dupuytren's Disease ◽  
Population Based Study ◽  
Classification Of Diseases ◽  
First Time

The prevalence and incidence of doctor-diagnosed Dupuytren’s disease in the general population is unknown. From the healthcare register for Skåne region (population 1.3 million) in southern Sweden, we identified all residents aged ⩾20 years (on 31 December 2013), who 1998 to 2013 had consulted a doctor and received the diagnosis Dupuytren’s disease (International Classification of Diseases 10th Revision code M720). During the 16 years, 7207 current residents (72% men) had been diagnosed with Dupuytren’s disease; the prevalence among men was 1.35% and among women 0.5%. Of all people diagnosed, 56% had received treatment (87% fasciectomy). In 2013, the incidence of first-time doctor-diagnosed Dupuytren’s disease among men was 14 and among women five per 10,000. The annual incidence among men aged ⩾50 years was 27 per 10,000. Clinically important Dupuytren’s disease is common in the general population. Level of evidence: III

A Comparison of the Direct Outcomes of Percutaneous Needle Fasciotomy and Limited Fasciectomy for Dupuytren’s Disease: A 6-Week Follow-Up Study

2006 ◽  
Vol 31 (5) ◽  
pp. 717-725 ◽  
Author(s):  
Annet L. van Rijssen ◽  
Feike S.J. Gerbrandy ◽  
Hein Ter Linden ◽  
Helen Klip ◽  
Paul M.N. Werker
Keyword(s):  
Dupuytren’S Disease ◽  
Dupuytren's Disease ◽  
Follow Up Study ◽  
Limited Fasciectomy
Sign in / Sign up

Export Citation Format

Share Document